Luciferase Reporter Cancer Cell Lines: Facilitate Your CAR-T Development WebinarOctober 13, 2022, at 12:00 PM ET
Chimeric antigen receptor (CAR)-T cells have displayed remarkable efficacy in treating malignant cancers, particularly liquid tumors. Evaluating the biofunction of CAR-T cells in vitro typically involves a series of labor-intensive co-culture experiments and immunoassays, where reproducibility remains a challenge during the validation of new CAR-T cells due to donor-to-donor variations and other possible factors. In this webinar, we present new luciferase reporter tumor cell lines that naturally express high levels of clinically relevant CAR-T target antigens on cell surface, such as CD19, CD20 and HER2. Additionally, we show how these versatile reporter lines can be utilized to examine the function of CAR-T cells.
- Luciferase reporter tumor cell lines naturally express high levels of clinically relevant CAR-T target antigens on cell surface, such as CD19, CD20 and HER2
- Our scientists engineered multiple ATCC authenticated tumor cell lines with common CAR-T target antigens to express the luciferase reporter
- The luciferase reporter system is a simple, robust, and highly sensitive means to measure biological processes and CAR-T cell cytotoxicity in a co-culture system
- ATCC scientists have tested that these luciferase reporter tumor cell lines can also be used in various CAR-T killing cancer ex vivo live cell imaging assays
John Foulke, MS
Lead Biologist, ATCC
John Foulke is a Lead Biologist in the Immuno-Oncology group in the R&D department at ATCC. John joined the ATCC cell biology R&D group in 2008, and he has led many projects centered on the development of novel cell lines and cell-based reporter systems to support cancer research community. His work is mainly focused on developing innovative cell models for research and drug discovery in the immuno-oncology field.